DNA 추출 서비스 시장 : 시장 예측(2026-2032년)

The DNA Extraction Services Market is projected to grow by USD 3.10 billion at a CAGR of 11.92% by 2032.

DNA Extraction Services: Executive Overview

DNA extraction services support research, clinical workflows, biotechnology development, forensics, agriculture, and other applications that require purified genetic material. Their value depends on sample quality, extraction chemistry, automation, contamination control, chain of custody, and compatibility with downstream sequencing, amplification, and analysis platforms. Demand is shaped by expanding genomic research, more varied sample types, and the need for reproducible laboratory operations.

Standardization, Automation, and Sample Diversity Are Reshaping Service Delivery

The landscape is shifting from manually intensive, single-purpose workflows toward standardized, automated, and application-specific processing. Providers and laboratories increasingly emphasize validated protocols, flexible capacity, rapid turnaround, traceability, and integration with laboratory information systems. At the same time, difficult materials-including degraded, low-input, environmental, archival, and noninvasive samples-are increasing the importance of specialized extraction methods and quality-control procedures.

Artificial Intelligence Strengthens Workflow Control Rather Than Replacing Laboratory Expertise

Artificial intelligence can improve DNA extraction services by supporting sample triage, protocol selection, anomaly detection, instrument scheduling, quality assessment, and demand planning. When linked with laboratory information systems, AI may help identify contamination risks, flag inconsistent yields, and prioritize repeat processing. Its effective use still depends on representative training data, validated performance, explainable decisions, cybersecurity, and human oversight, particularly in regulated clinical, forensic, and biobanking environments.

Regional Priorities Differ Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America emphasizes high-throughput genomics, clinical validation, biobanking, and automation. Europe places strong weight on data governance, quality systems, cross-border research coordination, and ethical handling of human samples. Asia-Pacific combines advanced sequencing capacity in several economies with rapidly expanding research and diagnostic infrastructure. Latin America is prioritizing access, local laboratory capability, and logistics across geographically dispersed populations. The Middle East is investing in precision-health and research infrastructure, while Africa presents substantial opportunities for locally appropriate workflows, workforce development, sample transport, and capacity building.

ASEAN, BRICS, the European Union, G7, GCC, and NATO Reveal Different Operating Priorities

ASEAN cooperation is relevant to cross-border research, infectious-disease surveillance, and uneven laboratory capacity. BRICS members reflect a broad mix of large populations, research systems, and domestic manufacturing ambitions. The European Union focuses on harmonized standards, privacy, interoperability, and collaborative research. G7 economies generally emphasize advanced automation, clinical quality, and translational science. GCC countries are strengthening centralized healthcare and genomics capabilities, while NATO members may also prioritize resilient supply chains, secure data handling, and forensic or defense-adjacent laboratory readiness.

Country-Level Conditions Shape Capacity, Compliance, and Partnership Models

Australia combines strong research institutions with geographic logistics challenges. Brazil and Mexico require scalable services that address regional diversity and sample transport. Canada emphasizes public research, biobanking, and regulated clinical workflows. China and India are expanding domestic genomics and laboratory capabilities across varied operating environments. France, Germany, Italy, Spain, and the United Kingdom combine mature research ecosystems with stringent quality and data requirements. Japan and South Korea emphasize precision, automation, and advanced laboratory integration. Russia's operating environment is influenced by supply-chain, collaboration, and regulatory constraints. The United States remains important for high-throughput research, clinical innovation, and specialized service demand.

Leaders Should Build Quality, Resilience, and Interoperability Into Service Strategies

Industry leaders should segment workflows by sample type and end use, then validate extraction performance against downstream applications rather than yield alone. Investment priorities should include automation where volume justifies it, robust contamination controls, digital chain of custody, transparent quality metrics, and redundant sourcing for critical consumables. Partnerships with hospitals, research institutions, biobanks, and public laboratories can improve access to representative samples and domain expertise. Organizations should also establish AI governance, protect genomic data throughout its lifecycle, and design regional operating models that account for regulation, logistics, workforce skills, and local infrastructure.

Methodology: Evidence-Based Synthesis of Service Drivers and Operating Conditions

This executive summary uses the defined DNA extraction services scope and organizes qualitative insights across technology, workflow, application, regulatory, geographic, and institutional dimensions. The assessment considers publicly observable drivers such as genomics adoption, laboratory automation, sample complexity, quality requirements, data governance, infrastructure, and supply-chain resilience. Regional, group, and country observations are presented as contextual comparisons rather than quantified market claims. No market estimates, market shares, forecasts, or company-specific assessments are included.

Reliable Extraction Is Becoming a Strategic Foundation for Genomic Workflows

DNA extraction services are evolving into an integrated laboratory capability in which reproducibility, traceability, automation, and sample-specific expertise are as important as purification itself. Organizations that connect validated wet-lab procedures with strong quality systems, secure data practices, resilient logistics, and responsible AI use will be better positioned to support diverse genomic applications. Regional adaptation and partnerships remain essential because infrastructure, regulation, and workforce readiness differ substantially across markets.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. DNA Extraction Services Market, by Technology

• 7.1. Introduction
• 7.2. Column Based
  • 7.2.1. Spin Column
  • 7.2.2. Vacuum Column
• 7.3. Magnetic Bead
  • 7.3.1. Oil Coated
  • 7.3.2. Superparamagnetic
• 7.4. Membrane Based
  • 7.4.1. Spin Membrane
  • 7.4.2. Vacuum Membrane
• 7.5. Precipitation
  • 7.5.1. Alcohol Based
  • 7.5.2. Salt Based

8. DNA Extraction Services Market, by Sample Type

• 8.1. Introduction
• 8.2. Blood
• 8.3. Cells
  • 8.3.1. Animal
  • 8.3.2. Bacterial
  • 8.3.3. Fungal
• 8.4. Plants
• 8.5. Tissue
  • 8.5.1. Normal Tissue
  • 8.5.2. Tumor Tissue

9. DNA Extraction Services Market, by Application

• 9.1. Introduction
• 9.2. Biopharmaceutical Production
  • 9.2.1. Therapeutic Antibodies
  • 9.2.2. Vaccine Development
• 9.3. Clinical Diagnostics
  • 9.3.1. Genetic Disease Testing
  • 9.3.2. Infectious Disease Testing
  • 9.3.3. Oncology Profiling
• 9.4. Forensics
  • 9.4.1. Crime Scene Investigation
  • 9.4.2. Paternity Testing
• 9.5. Research And Development
  • 9.5.1. Genomics Research
  • 9.5.2. Personalized Medicine

10. DNA Extraction Services Market, by End User

• 10.1. Introduction
• 10.2. Academic And Research Institutes
• 10.3. CROs
• 10.4. Hospitals And Diagnostic Labs
• 10.5. Pharmaceutical And Biotech Companies

11. DNA Extraction Services Market, by Region

• 11.1. Introduction
• 11.2. Asia-Pacific
• 11.3. North America
• 11.4. Latin America
• 11.5. Europe
• 11.6. Middle East
• 11.7. Africa

12. DNA Extraction Services Market, by Group

• 12.1. Introduction
• 12.2. ASEAN
• 12.3. GCC
• 12.4. European Union
• 12.5. BRICS
• 12.6. G7
• 12.7. NATO

13. DNA Extraction Services Market, by Country

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. United Kingdom
• 13.7. Germany
• 13.8. France
• 13.9. Russia
• 13.10. Italy
• 13.11. Spain
• 13.12. China
• 13.13. India
• 13.14. Japan
• 13.15. Australia
• 13.16. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. Market Concentration Analysis, 2025
  • 14.2.1. Concentration Ratio (CR)
  • 14.2.2. Herfindahl Hirschman Index (HHI)
• 14.3. Recent Developments & Impact Analysis, 2025
• 14.4. Product Portfolio Analysis, 2025
• 14.5. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Agilent Technologies, Inc.
• 15.2. Anthony Nolan Ltd.
• 15.3. AutoGen, LLC
• 15.4. Azenta, Inc.
• 15.5. BGI Genomics Co., Ltd.
• 15.6. Biofortuna Ltd.
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. Canopy Biosciences LLC
• 15.9. Cerba Research UK Ltd.
• 15.10. Creative Bioarray, Inc.
• 15.11. Daicel Arbor Biosciences Inc.
• 15.12. Danaher Corporation
• 15.13. DKMS Life Science Lab gGmbH
• 15.14. Eurofins Scientific SE
• 15.15. F. Hoffmann-La Roche Ltd
• 15.16. Kaizen Bioservices Pvt. Ltd.
• 15.17. LGC Biosearch Technologies Ltd.
• 15.18. Merck KGaA
• 15.19. PerkinElmer, Inc.
• 15.20. QIAGEN N.V.
• 15.21. Reprocell Holdings Ltd.
• 15.22. Source BioScience Ltd.
• 15.23. Takara Bio Inc.
• 15.24. Thermo Fisher Scientific Inc.

16. Key Experts